Francisco MartÃ-n

List of Publications by Year
in descending order

84 papers	2,570 citations	196777 29 h-index	242451 47 g-index
86 all docs	86 docs citations	86 times ranked	3851 citing authors

#	Article	IF	Citations
1	The mitochondrial pyruvate carrier regulates memory TÂcell differentiation and antitumor function. Cell Metabolism, 2022, 34, 731-746.e9.	7.2	63
2	Physiological lentiviral vectors for the generation of improved CAR-T cells. Molecular Therapy - Oncolytics, 2022, 25, 335-349.	2.0	4
3	Isogenic GAA-KO Murine Muscle Cell Lines Mimicking Severe Pompe Mutations as Preclinical Models for the Screening of Potential Gene Therapy Strategies. International Journal of Molecular Sciences, 2022, 23, 6298.	1.8	1
4	Baboon Envelope Pseudotyped â€œNanobladesâ€•Carrying Cas9/gRNA Complexes Allow Efficient Genome Editing in Human T, B, and CD34+ Cells and Knock-in of AAV6-Encoded Donor DNA in CD34+ Cells. Frontiers in Genome Editing, 2021, 3, 604371.	2.7	25
5	Anti-CD44-Conjugated Olive Oil Liquid Nanocapsules for Targeting Pancreatic Cancer Stem Cells. Biomacromolecules, 2021, 22, 1374-1388.	2.6	23
6	Improved Functionality of Integration-Deficient Lentiviral Vectors (IDLVs) by the Inclusion of IS2 Protein Docks. Pharmaceutics, 2021, 13, 1217.	2.0	3
7	LentiRILES, a miRNA-ON sensor system for monitoring the functionality of miRNA in cancer biology and therapy. RNA Biology, 2021, 18, 198-214.	1.5	4
8	Exosomes: Their Role in Pathogenesis, Diagnosis and Treatment of Diseases. Cancers, 2021, 13, 84.	1.7	36
9	Coenzyme Q10 modulates sulfide metabolism and links the mitochondrial respiratory chain to pathways associated to one carbon metabolism. Human Molecular Genetics, 2020, 29, 3296-3311.	1.4	16
10	Intracellular trafficking and functional monitoring of miRNA delivery in glioblastoma using lipopolyplexes and the miRNA-ON RILES reporter system. Journal of Controlled Release, 2020, 327, 429-443.	4.8	16
11	GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-Î². Cell Death and Disease, 2020, 11, 985.	2.7	14
12	Exosome: A New Player in Translational Nanomedicine. Journal of Clinical Medicine, 2020, 9, 2380.	1.0	47
13	WAS Promoter-Driven Lentiviral Vectors Mimic Closely the Lopsided WASP Expression during Megakaryocytic Differentiation. Molecular Therapy - Methods and Clinical Development, 2020, 19, 220-235.	1.8	4
14	Externally-Controlled Systems for Immunotherapy: From Bench to Bedside. Frontiers in Immunology, 2020, 11, 2044.	2.2	18
15	Using Gene Editing Approaches to Fine-Tune the Immune System. Frontiers in Immunology, 2020, 11, 570672.	2.2	13
16	Development of Cellular Models to Study Efficiency and Safety of Gene Edition by Homologous Directed Recombination Using the CRISPR/Cas9 System. Cells, 2020, 9, 1492.	1.8	1
17	Genomeâ€edited adult stem cells: Nextâ€generation advanced therapy medicinal products. Stem Cells Translational Medicine, 2020, 9, 674-685.	1.6	12
18	Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL. Leukemia, 2020, 34, 2722-2735.	3.3	24

#	Article	IF	Citations
19	GARP is a key molecule for mesenchymal stromal cell responses to TGF-Î² and fundamental to control mitochondrial ROS levels. Stem Cells Translational Medicine, 2020, 9, 636-650.	1.6	11
20	Stable Genetic Modification of Mesenchymal Stromal Cells Using Lentiviral Vectors. Methods in Molecular Biology, 2019, 1937, 267-280.	0.4	11
21	Human predecidual stromal cells are mesenchymal stromal/stem cells and have a therapeutic effect in an immune-based mouse model of recurrent spontaneous abortion. Stem Cell Research and Therapy, 2019, 10, 177.	2.4	33
22	Comparison of Zinc Finger Nucleases Versus CRISPR-Specific Nucleases for Genome Editing of the Wiskott-Aldrich Syndrome Locus. Human Gene Therapy, 2018, 29, 366-380.	1.4	33
23	The IS2 Element Improves Transcription Efficiency of Integration-Deficient Lentiviral Vector Episomes. Molecular Therapy - Nucleic Acids, 2018, 13, 16-28.	2.3	8
24	TGF-Î² and mesenchymal stromal cells in regenerative medicine, autoimmunity and cancer. Cytokine and Growth Factor Reviews, 2018, 43, 25-37.	3.2	87
25	Clinical and Functional Characterization of a Missense ELF2 Variant in a CANVAS Family. Frontiers in Genetics, 2018, 9, 85.	1.1	19
26	Exosomes derived from mesenchymal stem cells enhance radiotherapy-induced cell death in tumor and metastatic tumor foci. Molecular Cancer, 2018, 17, 122.	7.9	100
27	Neuronal apoptosis inhibitory protein (NAIP) localizes to the cytokinetic machinery during cell division. Scientific Reports, 2017, 7, 39981.	1.6	23
28	Gene therapy with mesenchymal stem cells expressing IFNâ€ÃŸ ameliorates neuroinflammation in experimental models of multiple sclerosis. British Journal of Pharmacology, 2017, 174, 238-253.	2.7	34
29	Allogeneic Adipose-Derived Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Regulating Self-Reactive T Cell Responses and Dendritic Cell Function. Stem Cells International, 2017, 2017, 1-15.	1.2	42
30	Gene Delivery Technologies for Efficient Genome Editing: Applications in Gene Therapy. , 2016, , .		0
31	Biased and Unbiased Methods for the Detection of Off-Target Cleavage by CRISPR/Cas9: An Overview. International Journal of Molecular Sciences, 2016, 17, 1507.	1.8	74
32	Lent-On-Plus Lentiviral vectors for conditional expression in human stem cells. Scientific Reports, 2016, 6, 37289.	1.6	16
33	Genome editing: An alternative to retroviral vectors for Wiskott-Aldrich Syndrome (WAS) Gene Therapy?. Expert Opinion on Orphan Drugs, 2016, 4, 281-289.	0.5	1
34	NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells. Cancer Letters, 2016, 375, 92-99.	3.2	6
35	Absence of WASp Enhances Hematopoietic and Megakaryocytic Differentiation in a Human Embryonic Stem Cell Model. Molecular Therapy, 2016, 24, 342-353.	3.7	8
36	Gene Therapy Corrects Mitochondrial Dysfunction in Hematopoietic Progenitor Cells and Fibroblasts from Coq9R239X Mice. PLoS ONE, 2016, 11, e0158344.	1.1	2

#	Article	IF	Citations
37	342. Gene Edition for Wiskott-Aldrich Syndrome Gene Therapy. Molecular Therapy, 2015, 23, S136.	3.7	0
38	Mesenchymal Stromal Cells Express GARP/LRRC32 on Their Surface: Effects on Their Biology and Immunomodulatory Capacity. Stem Cells, 2015, 33, 183-195.	1.4	51
39	SCL/TAL1-mediated Transcriptional Network Enhances Megakaryocytic Specification of Human Embryonic Stem Cells. Molecular Therapy, 2015, 23, 158-170.	3.7	25
40	Isolation of Murine Adipose Tissue-derived Mesenchymal Stromal Cells (mASCs) and the Analysis of Their Proliferation in vitro. Bio-protocol, 2015, 5, .	0.2	3
41	A Chimeric HS4-SAR Insulator (IS2) That Prevents Silencing and Enhances Expression of Lentiviral Vectors in Pluripotent Stem Cells. PLoS ONE, 2014, 9, e84268.	1.1	33
42	Gene-modified mesenchymal stromal cells: A VIP experience. Inflammation and Regeneration, 2014, 34, 176-183.	1.5	0
43	Peripheral nerve reconstruction with epsilon-caprolactone conduits seeded with vasoactive intestinal peptide gene-transfected mesenchymal stem cells in a rat model. Journal of Neural Engineering, 2014, 11, 046024.	1.8	9
44	Contractile activity of human follicular dendritic cells. Immunology and Cell Biology, 2014, 92, 851-859.	1.0	13
45	SCL/TAL1-mediated transcriptional network enhances megakaryocytic specification of human embryonic stem cells. Experimental Hematology, 2014, 42, S50.	0.2	0
46	Specific calcineurin targeting in macrophages confers resistance to inflammation via MKPâ€1 and p38. EMBO Journal, 2014, 33, 1117-1133.	3.5	29
47	Use of zinc-finger nucleases to knock out theWASgene in K562 cells: a human cellular model for Wiskott-Aldrich syndrome. DMM Disease Models and Mechanisms, 2013, 6, 544-54.	1.2	16
48	Mesenchymal Stem Cells Expressing Vasoactive Intestinal Peptide Ameliorate Symptoms in a Model of Chronic Multiple Sclerosis. Cell Transplantation, 2013, 22, 839-854.	1.2	42
49	CD105 (Endoglin)-Negative Murine Mesenchymal Stromal Cells Define a New Multipotent Subpopulation with Distinct Differentiation and Immunomodulatory Capacities. PLoS ONE, 2013, 8, e76979.	1.1	126
50	Maintenance of Human Embryonic Stem Cells in Mesenchymal Stem Cell-Conditioned Media Augments Hematopoietic Specification. Stem Cells and Development, 2012, 21, 1549-1558.	1.1	27
51	Specific Marking of hESCs-Derived Hematopoietic Lineage by WAS-Promoter Driven Lentiviral Vectors. PLoS ONE, 2012, 7, e39091.	1.1	13
52	Apoptotic DC-SIGN+ cells in normal human decidua. Placenta, 2012, 33, 257-263.	0.7	16
53	New Vectors for Stable and Safe Gene Modification. , 2011, , .		1
54	Development of an All-in-One Lentiviral Vector System Based on the Original TetR for the Easy Generation of Tet-ON Cell Lines. PLoS ONE, 2011, 6, e23734.	1.1	37

#	Article	IF	Citations
55	Physiological and tissue-specific vectors for treatment of inherited diseases. Gene Therapy, 2011, 18, 117-127.	2.3	47
56	A tissue-specific, activation-inducible, lentiviral vector regulated by human CD40L proximal promoter sequences. Gene Therapy, 2011, 18, 364-371.	2.3	32
57	Dendritic Cells Transduced With Lentiviral Vectors Expressing VIP Differentiate Into VIP-secreting Tolerogenic-like DCs. Molecular Therapy, 2010, 18, 1035-1045.	3.7	63
58	WascDNA Sequences Modulate Transgene Expression ofWasPromoter-Driven Lentiviral Vectors. Human Gene Therapy, 2009, 20, 1279-1290.	1.4	4
59	A Lentiviral Vector That Activates Latent Human Immunodeficiency Virus-1 Proviruses by the Overexpression of Tat and That Kills the Infected Cells. Human Gene Therapy, 2009, 20, 1259-1268.	1.4	8
60	Safer Vectors for Gene Therapy of Primary Immunodeficiencies. Current Gene Therapy, 2009, 9, 291-305.	0.9	5
61	In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagenâ€induced arthritis. Arthritis and Rheumatism, 2008, 58, 1026-1037.	6.7	53
62	Improved lentiviral vectors for Wiskottâ€“Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis. Gene Therapy, 2008, 15, 930-941.	2.3	34
63	Hematopoietic-Specific Lentiviral Vectors Circumvent Cellular Toxicity Due to Ectopic Expression of Wiskott-Aldrich Syndrome Protein. Human Gene Therapy, 2008, 19, 179-198.	1.4	32
64	Transplantation of human CD34+stem cells from umbilical cord blood to rats with thioacetamide-induced liver cirrhosis. Xenotransplantation, 2006, 13, 529-535.	1.6	27
65	Follicular Dendritic Cells Are Related to Bone Marrow Stromal Cell Progenitors and to Myofibroblasts. Journal of Immunology, 2006, 177, 280-289.	0.4	117
66	Conjugation of Lentivirus to Paramagnetic Particles via Nonviral Proteins Allows Efficient Concentration and Infection of Primary Acute Myeloid Leukemia Cells. Journal of Virology, 2005, 79, 13190-13194.	1.5	38
67	Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences. Gene Therapy, 2005, 12, 715-723.	2.3	55
68	Contractile Activity of Human Decidual Stromal Cells. II. Effect of Interleukin-10. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6126-6130.	1.8	23
69	Efficient Retroviral Vector Targeting of Carcinoembryonic Antigen-Positive Tumors. Molecular Therapy, 2004, 9, 85-92.	3.7	22
70	Efficient lentiviral transduction of Herpesvirus saimiri immortalized T cells as a model for gene therapy in primary immunodeficiencies. Gene Therapy, 2004, 11, 956-961.	2.3	28
71	Continuous high-titer HIV-1 vector production. Nature Biotechnology, 2003, 21, 569-572.	9.4	172
72	Targeted Retroviral Infection of Tumor Cells by Receptor Cooperation. Journal of Virology, 2003, 77, 2753-2756.	1.5	15

#	Article	IF	Citations
73	Envelope-Targeted Retrovirus Vectors Transduce Melanoma Xenografts but Not Spleen or Liver. Molecular Therapy, 2002, 5, 269-274.	3.7	35
74	Postentry Restriction to Human Immunodeficiency Virus-Based Vector Transduction in Human Monocytes. Journal of Virology, 2001, 75, 5448-5456.	1.5	125
75	Retroviral Display of Functional Binding Domains Fused to the Amino Terminus of Influenza Hemagglutinin. Human Gene Therapy, 1999, 10, 1533-1544.	1.4	57
76	Retrovirus Targeting by Tropism Restriction to Melanoma Cells. Journal of Virology, 1999, 73, 6923-6929.	1.5	51
77	Retroviral Vector Targeting to Melanoma Cells by Single-Chain Antibody Incorporation in Envelope. Human Gene Therapy, 1998, 9, 737-746.	1.4	55
78	Reverse transcriptase-like activity in Trypanosoma cruzi. Acta Tropica, 1997, 63, 117-126.	0.9	6
79	Identification of a Trypanosoma cruzi antigenic epitope implicated in the infectivity of fibroblast LLC-MK2 cells. Parasitology Research, 1997, 83, 226-232.	0.6	4
80	Do non-long terminal repeat retrotransponsons have nuclease activity?. Trends in Biochemical Sciences, 1996, 21, 283-285.	3.7	13
81	Characterization of a Non-long Terminal Repeat Retrotransposon cDNA (L1Tc) fromTrypanosoma cruzi: Homology of the First ORF with the Ape Family of DNA Repair Enzymes. Journal of Molecular Biology, 1995, 247, 49-59.	2.0	139
82	Characterization of a short interspersed reiterated DNA sequence of Trypanosoma cruzi located at the 3â€²-end of a poly(A)+ transcript. Gene, 1994, 146, 245-250.	1.0	15
83	Cytoplasmic-Nuclear Translocation of the HSP70 Protein during Environmental Stress in Trypanosoma cruzi. Biochemical and Biophysical Research Communications, 1993, 196, 1155-1162.	1.0	20
84	Gene Therapy for Primary Immunodeficiencies. , 0, , .		0